Curosurf market report points to steady growth in neonatal care demand

The Business Research Company says the Curosurf (poractant alfa) market is set for steady expansion as premature births rise and neonatal intensive care use grows. North America led the market in 2025, while Asia-Pacific is projected to grow fastest through the forecast period.

Why it matters: - Curosurf (poractant alfa) is used to prevent and treat respiratory distress syndrome in premature infants, making it a core therapy in neonatal care. - The market’s growth tracks broader pressures in neonatal and respiratory health, including more preterm births and wider NICU adoption. - The report also points to regional shifts that matter for hospital systems, drug suppliers, and neonatal care providers.

What happened: - The Business Research Company released a Curosurf (poractant alfa) market analysis report on November 2, 2026. - The report says the market is gaining attention because of its role in treating respiratory distress syndrome among premature infants. - North America held the largest market share in 2025. - Asia-Pacific is projected to be the fastest-growing region over the forecast period. - The report covers Western Europe, Eastern Europe, South America, the Middle East, and Africa as part of its global market view.

The details: - Curosurf is described as a pulmonary surfactant that mimics a natural lung substance and helps reduce surface tension in the alveoli. - The therapy helps keep the tiny air sacs in the lungs open and supports breathing in vulnerable newborns. - Market growth has historically been driven by high preterm birth rates, treatment effectiveness, NICU adoption, clinical guidelines supporting surfactant therapy, and declining neonatal mortality. - Future growth is expected to come from more premature births worldwide, larger NICU capacity, better access to neonatal care, greater awareness of early RDS intervention, and continued clinical support. - The report highlights growing NICU use, rising preference for synthetic surfactants, standardization of RDS treatment protocols, and more hospital-based neonatal treatment. - The report also lists respiratory disorders such as asthma, COPD, and lung cancer as a demand driver because worsening air pollution and an aging population are increasing their prevalence. - The National Library of Medicine projected in December 2023 that COPD cases among people age 25 and older will rise 23% by 2050 to nearly 600 million globally. - The UK Office for National Statistics said in July 2025 that England and Wales recorded 594,677 live births in 2024, up 0.6% from 591,072 in 2023. - The report links that birth trend to rising demand for Curosurf in premature infants with respiratory distress syndrome. - The report’s 2026 update adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technology and future trend analysis, and updated graphics and tables. - The report offers a free sample and full report through the company’s sample request page and the full market report.

Between the lines: - The report frames Curosurf demand as part of a larger neonatal care market that is becoming more standardized and data-driven. - The emphasis on forecast dashboards and scoring tools suggests buyers and investors are being pushed toward more granular market screening, not just broad growth estimates. - The regional split points to a mature market in North America and a higher-growth opportunity in emerging health systems across Asia-Pacific.

What's next: - The report expects demand to keep rising as NICUs expand and neonatal care access improves. - Market adoption will likely keep following the pace of preterm birth rates, neonatal treatment protocols, and hospital infrastructure growth. - The Business Research Company is positioning the 2026 report update as a more detailed planning tool for market tracking and competitive analysis. - More information is available through the company’s LinkedIn page.